Assessment of the dual role of Lyonia ovalifolia (Wall.) Drude in inhibiting AGEs and enhancing GLUT4 translocation through LC-ESI-QTOF-MS/MS determination and in silico studies

Neha Sahu; Nitesh Singh; Kamal Ram Arya; Sabbu Sathish Reddy; Amit Kumar Rai; Vijaya Shukla; Jyotsana Pandey; Tadigoppula Narender; Akhilesh Kumar Tamrakar; Brijesh Kumar; Bikash Kumar Rajak; Sumira Malik; Sarvesh Rustagi

doi:10.3389/fphar.2023.1073327

Assessment of the dual role of Lyonia ovalifolia (Wall.) Drude in inhibiting AGEs and enhancing GLUT4 translocation through LC-ESI-QTOF-MS/MS determination and in silico studies

Front Pharmacol. 2023 Mar 27:14:1073327. doi: 10.3389/fphar.2023.1073327. eCollection 2023.

Authors

Affiliations

¹ Department of Botany, University of Lucknow, Lucknow, India.
² Botany Division, CSIR-Central Drug Research Institute, Lucknow, India.
³ Department of Plant Pathology, Faculty of Agriculture Sciences, SGT University, Gurugram, India.
⁴ Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, India.
⁵ Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow, India.
⁶ Sophisticated Analytical Instrument Facility, CSIR-Central Drug Research Institute, Lucknow, India.
⁷ Department of Bioinformatics, Central University of South Bihar, Gaya, India.
⁸ Amity Institute of Biotechnology, Amity University, Ranchi, Jharkhand, India.
⁹ Department of Food Technology, School of Applied and Life sciences, Uttaranchal University, Dehradun, Uttarakhand, India.

Abstract

Introduction: Diabetes mellitus (DM) is a metabolic disorder that results in glucose accumulation in the blood, accompanied by the production of advanced glycation end products (AGEs) through glycation of cellular proteins. These AGEs interfere with insulin signaling and prevent GLUT4 membrane translocation, thereby promoting the accumulation of more glucose in the blood and causing post-diabetic complications. Methods: In this study, we examine the anti-diabetic potential of Lyonia ovalifolia (Wall.) Drude, a well-known ethnomedicinal plant of the Indian Himalayas. Considering its various medicinal properties, we analyzed its ethanolic extract and various solvent fractions for in vitro antiglycation activity and antidiabetic potential, i.e., stimulation of GLUT4 translocation. Result and Discussions: The results showed that the extract and fractions exhibited increased antiglycation activity and an increased level of GLUT4 translocation. Analysis of a further 12 bioactive compounds of ethanolic extract, identified through LC-ESI-QTOF-MS/MS, revealed the presence of three new compounds: leucothol B, rhodoterpenoids A, and leucothol A. Moreover, we performed molecular docking of identified compounds against key proteins of diabetes mellitus: the sirtuin family of NAD (+)-dependent protein deacetylases 6 (SIRT6), aldose reductase (AR), and tyrosine kinase (TK). The results showed that flavonoid luteolin showed the best binding affinity ((-12.3 kcal/mol), followed by eriodictyol, astilbin, and syringaresinol. An ADMET study showed that luteolin, eriodictyol, astilbin, and syringaresinol may be promising drug candidates belonging to the flavonoid class of compounds, with no harmful effects and complying with all the drug-likeness guidelines. Furthermore, molecular dynamics (MD) simulations on a 50 ns timescale revealed that AR protein was most stable with luteolin throughout the simulation period. Therefore, this study reveals for the first time that L. ovalifolia plays an important role in insulin homeostasis, as shown in in vitro and in silico studies.

Keywords: Bioactivity guided fractionation; Ericaceae; GLUT4 translocation; Lyonia ovalifolia; flavonoids; protein glycation.